Table 1.
Summary characteristics of the overall sample stratified by radiation treatment before and after propensity score matching
| Variables | Overall sample (n = 3181) | Propensity‐matched sample (n = 616) | ||||
|---|---|---|---|---|---|---|
| Radiation (n = 308) | Control (n = 2873) | P value | Radiation (n = 308) | Control (n = 308) | P value | |
| Age (y) | ||||||
| ≤65 | 212 (68.8) | 2020 (70.3) | 0.59 | 212 (68.8) | 204 (66.2) | 0.491 |
| >65 | 96 (31.2) | 853 (29.7) | 96 (31.2) | 104 (33.8) | ||
| Sex | ||||||
| Male (%) | 251 (81.5) | 2393 (83.3) | 0.423 | 251 (81.5) | 250 (81.2) | 0.918 |
| Female (%) | 57 (18.5) | 480 (16.7) | 57 (18.5) | 58 (18.8) | ||
| Marital status | ||||||
| Married (%) | 189 (61.4) | 1489 (51.8) | 0.003 | 189 (61.4) | 155 (50.3) | <0.001 |
| Single and unmarried (%) | 45 (14.6) | 659 (22.9) | 45 (14.6) | 86 (27.9) | ||
| Widowed, divorced, separated (%) | 60 (19.5) | 596 (20.7) | 60 (19.5) | 63 (20.5) | ||
| Unknown (%) | 14 (4.5) | 129 (4.5) | 14 (4.5) | 4 (1.3) | ||
| Race | ||||||
| White (%) | 224 (72.7) | 1852 (64.5) | 0.014 | 224 (72.7) | 180 (58.4) | <0.001 |
| Black (%) | 43 (14.0) | 451 (15.7) | 43 (14.0) | 46 (14.9) | ||
| Other (%) | 41 (13.3) | 551 (19.2) | 41 (13.3) | 82 (26.6) | ||
| Unknown (%) | 0 (0.0) | 19 (0.7) | ||||
| Tumor size | ||||||
| ≤1 cm (%) | 0 (0.0) | 14 (0.15) | 0.008 | 0 (0.0) | 3 (1.0) | 0.048 |
| 1‐3 cm (%) | 26 (8.4) | 209 (7.3) | 26 (8.4) | 18 (5.8) | ||
| 3‐5 cm (%) | 47 (15.3) | 368 (12.8) | 47 (15.3) | 46 (14.9) | ||
| >5 cm (%) | 185 (60.1) | 1563 (54.4) | 185 (60.1) | 168 (54.5) | ||
| Unknown (%) | 50 (16.2) | 719 (25.0) | 50 (16.2) | 73 (23.7) | ||
| Vascular invasion | ||||||
| Code 630 (%) | 185 (60.1) | 1834 (63.8) | 0.23 | 185 (60.1) | 193 (62.7) | 0.395 |
| Code 635 (%) | 87 (28.2) | 685 (23.8) | 87 (28.2) | 73 (23.7) | ||
| Code 660 (%) | 36 (11.7) | 354 (12.3) | 36 (11.7) | 42 (13.6) | ||
| TNM/T | ||||||
| T3 (%) | 272 (88.3) | 2519 (87.7) | 0.747 | 272 (88.3) | 266 (86.4) | 0.467 |
| T4 (%) | 36 (11.7) | 354 (12.3) | 36 (11.7) | 42 (13.6) | ||
| Lymph nodes | ||||||
| N0 (%) | 232 (75.3) | 2020 (70.3) | 0.02 | 232 (75.3) | 209 (67.9) | 0.121 |
| N1 (%) | 51 (16.6) | 457 (15.9) | 51 (16.6) | 66 (21.4) | ||
| Nx (%) | 25 (8.1) | 396 (13.8) | 25 (8.1) | 33 (10.7) | ||
| Distant metastasis | ||||||
| M0 (%) | 213 (69.2) | 2038 (70.9) | 0.038 | 213 (69.2) | 214 (69.5) | 0.891 |
| M1 (%) | 85 (27.6) | 660 (23.0) | 85 (27.6) | 86 (27.9) | ||
| Mx (%) | 10 (3.2) | 175 (6.1) | 10 (3.2) | 8 (2.6) | ||
| Derived AJCC Stage Group (6th) | ||||||
| III (%) | 213 (69.2) | 2038 (70.9) | 0.038 | 213 (69.2) | 214 (69.5) | 0.891 |
| IV (%) | 85 (27.6) | 660 (23.0) | 85 (27.6) | 86 (27.9) | ||
| Unk stage (%) | 10 (3.2) | 175 (6.1) | 10 (3.2) | 8 (2.6) | ||
| Grade (differentiated) | ||||||
| Well (%) | 32 (10.4) | 186 (6.5) | 0.018 | 32 (10.4) | 26 (8.4) | 0.088 |
| Moderately (%) | 41 (13.3) | 335 (11.7) | 41 (13.3) | 35 (11.4) | ||
| Poorly (%) | 32 (10.4) | 222 (7.7) | 32 (10.4) | 19 (6.2) | ||
| Undifferentiated/anaplastic (%) | 2 (0.6) | 22 (0.8) | 2 (0.6) | 0 (0.0) | ||
| Unknown (%) | 201 (65.3) | 2108 (73.4) | 201 (65.3) | 228 (74.0) | ||
| AFP | ||||||
| Elevated (%) | 233 (75.6) | 2198 (76.5) | 0.646 | 233 (75.6) | 222 (72.1) | 0.568 |
| Within normal limits (%) | 36 (11.7) | 289 (10.1) | 36 (11.7) | 39 (12.7) | ||
| Unknown (%) | 39 (12.7) | 386 (13.4) | 39 (12.7) | 47 (15.3) | ||
| Fibrosis score | ||||||
| 0‐4 (F0) (%) | 13 (4.2) | 108 (3.8) | 0.136 | 13 (4.2) | 19 (6.2) | 0.525 |
| 5‐6 (F1) (%) | 80 (26.0) | 611 (21.3) | 80 (26.0) | 75 (24.4) | ||
| Unknown (%) | 215 (69.8) | 2154 (75.0) | 215 (69.8) | 214 (69.5) | ||
AJCC, American Joint Committee on Cancer.